Centrum für Hämatologie und Onkologie Bethanien

Industry / private company


Location: Frankfurt/Main, Germany (DE) DE

ISNI: -


close-button

Types of publications

Journal article
Book chapter / Article in edited volumes
Authored book
Translation
Thesis
Edited Volume
Conference contribution
Other publication type
Unpublished / Preprint

Publication year

From
To

Abstract

Journal

Clinical restenosis and its predictors after implantation of everolimus-eluting bioresorbable vascular scaffolds: results from GABI-R (2017) Mehilli J, Achenbach S, Woehrle J, Baquet M, Riemer T, Muenzel T, Nef HM, et al. Journal article Genetic Breast Cancer Susceptibility Variants and Prognosis in the Prospectively Randomized SUCCESS A Study (2017) Hein A, Rack B, Li L, Ekici AB, Reis A, Lux MP, Cunningham JM, et al. Journal article Implementation and Feasibility of Electronic Patient-Reported Outcome (ePRO) Data Entry in the PRAEGNANT Real-Time Advanced and Metastatic Breast Cancer Registry (2017) Wallwiener M, Heindl F, Brucker SY, Taran FA, Hartkopf A, Overkamp F, Kolberg HC, et al. Journal article DasPAQT: Treating Patients with Chronic Myeloid Leukemia (CML) in Chronic Phase (CP) with Dasatinib - PCR-Monitoring, Adherence, Quality of Life, Therapy Satisfaction (OMC 2014-I; BMS CA180-565) (2016) Tesch H, Pelz H, Janssen J, Hansen R, Fietz T, Anhuf J, Häberle L, et al. Conference contribution Serum carbonic anhydrase IX as predictive marker for efficacy of bevacizumab: a biomarker analysis from the GeparQuinto phase III neoadjuvant breast cancer trial (2016) Janning M, Mueller , Vettorazzi E, Cubas-Cordova M, Gensch , Ben Batalla , Eulenburg ZC, et al. Conference contribution Tumor-infiltrating lymphocytes and response prediction to neoadjuvant chemotherapy in HER2-positive breast cancer (2016) Heppner BI, Untch M, Denkert C, Pfitzner BM, Lederer B, Schmidt W, Eidtmann H, et al. Conference contribution Zoledronate for patients with invasive residual disease after anthracyclines-taxane-based chemotherapy for early breast cancer - The Phase III NeoAdjuvant Trial Add-oN (NaTaN) study (GBG 36/ABCSG 29) (2016) Von Minckwitz G, Rezai M, Tesch H, Huober J, Gerber B, Zahm DM, Hilfrich J, et al. Journal article Tumor-Infiltrating Lymphocytes: A Predictive and Prognostic Biomarker in Neoadjuvant-Treated HER2-Positive Breast Cancer (2016) Heppner BI, Untch M, Denkert C, Pfitzner BM, Lederer B, Schmitt W, Eidtmann H, et al. Journal article Factors Influencing Decision-Making for or against Adjuvant and Neoadjuvant Chemotherapy in Postmenopausal Hormone Receptor-Positive Breast Cancer Patients in the EvAluate-TM Study (2016) Gaß P, Fasching P, Fehm T, De Waal J, Rezai M, Baier B, Baake G, et al. Journal article Detection of circulating tumor cells using manually performed immunocytochemistry (MICC) does not correlate with outcome in patients with early breast cancer - Results of the German SUCCESS-A- trial (2016) Jueckstock J, Rack B, Friedl TWP, Scholz C, Steidl J, Trapp E, Tesch H, et al. Journal article